Relapsed/refractory lymphoma patients may be prescribed anti-CD30 monoclonal antibody therapy, brentuximab vedotin, to target tumor cells; however, anti-CD30 drugs could diminish PZA activity in TB co-infected patients and consequently promote PZA resistance in Mtb (48, 49). This evidence concerns the gene TNFRSF8 and neoplasm.